SOURCE: Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP

October 10, 2014 18:37 ET

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Pacira Pharmaceuticals, Inc. (PCRX) to Contact the Firm

NEW YORK, NY--(Marketwired - October 10, 2014) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of the December 2, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Pacira and certain executives.

A complaint has been filed in the District of New Jersey on behalf of all persons who purchased Pacira securities from April 9, 2012 through September 24, 2014, inclusive (the "Class Period").

The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.
Specifically, the action alleges that during the Class Period, Pacira falsely stated that one its drugs, EXPAREL, was effective for pain relief for up to 72 hours and safe for use in cholecystectomy and colectomy procedures, and failed to disclose that a substantial portion of the Company's revenues were derived from off-label marketing.
On September 25, 2014, Pacira announced that it had received a Warning Letter from the U.S. Food and Drug Administration's Office of Prescription Drug Promotion regarding EXPAREL's efficacy.

Following this news, the price of Pacira stock declined by $11.66, or over 10%, to close at $94.62 on September 25, 2014.

Request more information now by clicking here: www.faruqilaw.com/PCRX. There is no cost or obligation to you.

Take Action

If you invested in Pacira stock, bonds or options between April 9, 2012 through September 24, 2014, and would like to discuss your legal rights, visit www.faruqilaw.com/PCRX. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Pacira's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Contact Information

  • FARUQI & FARUQI, LLP
    369 Lexington Avenue, 10th Floor
    New York, NY 10017
    Attn: Richard Gonnello, Esq.
    rgonnello@faruqilaw.com
    Telephone: (877) 247-4292 or (212) 983-9330